Review
Oncology
Pier Francesco Ferrucci, Laura Pala, Fabio Conforti, Emilia Cocorocchio
Summary: Talimogene laherparepvec (T-VEC) is an oncolytic viral immunotherapy approved for the treatment of melanoma, aiming to trigger immune responses locally and potentially synergize with immune checkpoint inhibitors.
Article
Oncology
Evalyn E. A. P. Mulder, Emma H. A. Stahlie, Danielle Verver, Clara Lemstra, Lukas B. Been, Antien L. Mooyaart, Tessa Brabander, Erik Vegt, Frederik A. Verburg, Astrid A. M. van der Veldt, Cornelis Verhoef, Alexander C. J. van Akkooi, Dirk J. Grunhagen
Summary: T-VEC treatment may lead to new FDG uptake in locoregional lymph nodes, which could be falsely classified as suspected metastases. Physicians should be cautious of the high false positive rate of FDG uptake during T-VEC treatment and consider pathological examination of lymph node lesions to differentiate between disease progression and immune infiltration.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Review
Medicine, General & Internal
Tiantian Zhang, Tony Hong-Ting Jou, Jerline Hsin, Zhe Wang, Kelly Huang, Jian Ye, Holly Yin, Yan Xing
Summary: The past decade has witnessed a significant revolution in melanoma treatment. Oncolytic viruses (OVs) have emerged as a promising therapeutic approach for selectively infecting and killing tumor cells, as well as inducing anti-tumor immune responses. Talimogene laherparepvec (T-VEC), a genetically modified herpes simplex virus (HSV), is the first OV approved by the FDA for melanoma treatment and has shown promising therapeutic effects both as a monotherapy and in combination with other immunotherapies. This article provides a comprehensive review of OVs and the application of T-VEC in melanoma treatment, as well as its recent progress in other cutaneous cancer types. Furthermore, the authors share their experience of T-VEC therapy at City of Hope, aiming to provide further insights for expanding its future application.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, Research & Experimental
Alexander C. J. van Akkooi, Sebastian Haferkamp, Sophie Papa, Viola Franke, Andreas Pinter, Carsten Weishaupt, Margit A. Huber, Carmen Loquai, Erika Richtig, Priya Gokani, Katarina Ohrling, Karly S. Louie, Peter Mohr
Summary: This study examined the real-world use of T-VEC for unresectable melanoma in four European countries, with differences noted in the use of T-VEC between countries, particularly in the Netherlands where it was used in earlier disease stages and as a first-line therapy.
ADVANCES IN THERAPY
(2021)
Article
Oncology
Hatem Soliman, Deanna Hogue, Hyo Han, Blaise Mooney, Ricardo Costa, Marie C. Lee, Bethany Niell, Angela Williams, Alec Chau, Shannon Falcon, Nazanin Khakpour, Robert J. Weinfurtner, Susan Hoover, John Kiluk, Marilin Rosa, Hung Khong, Brian Czerniecki
Summary: The study combined TVEC and NAC for TNBC treatment, with postoperative evaluation using RCB. It found that adding TVEC at approved dose was feasible and resulted in a complete response rate of 55%. Most patients tolerated the treatment well with manageable toxicities.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Emma H. A. Stahlie, Evalyn E. A. P. Mulder, Sophie Reijers, Sara Balduzzi, Charlotte L. Zuur, Willem M. C. Klop, Bernies van der Hiel, Bart A. Van de Wiel, Michel W. J. M. Wouters, Yvonne M. Schrage, Winan J. van Houdt, Dirk J. Grunhagen, Alexander C. J. van Akkooi
Summary: Single-agent T-VEC is effective and well-tolerated in the treatment of unresectable and injectable stage III-IV melanoma, achieving high response rates especially in early metastatic melanoma patients.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
R. Dummer, D. E. Gyorki, J. Hyngstrom, A. C. Berger, R. Conry, L. Demidov, A. Sharma, S. A. Treichel, H. Radcliffe, K. S. Gorski, A. Anderson, E. Chan, M. Faries, M. I. Ross
Summary: The study found that intralesional injection of an oncolytic virus prior to surgery is clinically beneficial for patients with locally advanced, resectable melanoma, leading to improved recurrence-free survival.
Article
Oncology
Josep Malvehy, Igor Samoylenko, Dirk Schadendorf, Ralf Gutzmer, Jean-Jacques Grob, Joseph J. Sacco, Kevin S. Gorski, Abraham Anderson, Cheryl A. Pickett, Kate Liu, Helen Gogas
Summary: This study demonstrates that T-VEC induces systemic immune activity and modifies the tumor microenvironment, potentially enhancing the efficacy of combination immunotherapy with other agents.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biotechnology & Applied Microbiology
Mohammad Fazel, Neda AlRawashdh, Ahmad Alamer, Clara Curiel-Lewandrowski, Ivo Abraham
Summary: The research conducted an indirect comparison and found that T-VEC + IPI may significantly improve overall survival compared to using T-VEC alone in treating melanoma. This suggests that adding T-VEC to advanced melanoma treatment regimens as salvage therapy could be beneficial for select patients.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Article
Pharmacology & Pharmacy
Malidi Ahamadi, Johannes Kast, Po-Wei Chen, Xiaojun Huang, Sandeep Dutta, Vijay V. V. Upreti
Summary: T-VEC is a first-in-class oncolytic virotherapy approved for unresectable melanoma recurrent. Our analysis found that viral infection rate greatly influences T-VEC treatment efficacy, increasing T-VEC dose resulted in a 12% increase in response, and the ratio of resting innate immune cells to the death rate of innate immune impacts T-VEC treatment efficacy at the systemic level.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
(2023)
Article
Oncology
Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Erica Park, Grant A. McArthur
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Omid Hamid, Rubina Ismail, Igor Puzanov
Article
Oncology
Janice M. Mehnert, Emily Bergsland, Bert H. O'Neil, Armando Santoro, Jan H. M. Schellens, Roger B. Cohen, Toshihiko Doi, Patrick A. Ott, Michael J. Pishvaian, Igor Puzanov, Kyaw L. Aung, Chiun Hsu, Christophe Le Tourneau, Antoine Hollebecque, Elena Elez, Kenji Tamura, Marlena Gould, Ping Yang, Karen Stein, Sarina A. Piha-Paul
Editorial Material
Medicine, Research & Experimental
Franco Maria Buonaguro, Igor Puzanov, Paolo Antonio Ascierto
JOURNAL OF TRANSLATIONAL MEDICINE
(2020)
Article
Medicine, Research & Experimental
Paolo A. Ascierto, Sanjiv S. Agarwala, Alexander Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Olivier Michielin, Michael Postow, Igor Puzanov, Hassane M. Zarour, Corrado Caraco, Alessandro Testori
JOURNAL OF TRANSLATIONAL MEDICINE
(2020)
Review
Oncology
Rohit Gosain, Yara Abdou, Abhay Singh, Navpreet Rana, Igor Puzanov, Marc S. Ernstoff
CURRENT ONCOLOGY REPORTS
(2020)
Article
Multidisciplinary Sciences
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood, Sebastiano Battaglia, Saby George, Gurkamal Chatta, Igor Puzanov, Carl Morrison, Kunle Odunsi, Brahm H. Segal, Grace K. Dy, Marc S. Ernstoff, Fumito Ito
Summary: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but durable response is limited. CX3CR1, a marker of T-cell differentiation, is investigated as a predictor of response to ICI therapy. Treatment with ICI increases the frequency of circulating CX3CR1(+)CD8(+) T cells and correlates with response and survival in patients with non-small cell lung cancer.
NATURE COMMUNICATIONS
(2021)
Review
Oncology
Benjamin Switzer, Igor Puzanov, Joseph J. Skitzki, Lamya Hamad, Marc S. Ernstoff
Summary: This review summarizes the historical and future advances regarding the translational and clinical implications of advanced melanoma and provides multidisciplinary recommendations to aid clinicians in the navigation of current treatment approaches for a variety of patient cohorts.
JCO ONCOLOGY PRACTICE
(2022)
Article
Oncology
Jason A. Chesney, Antoni Ribas, Georgina Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari VanderWalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen Gogas
Summary: In this phase III study, the combination of T-VEC and pembrolizumab did not significantly improve progression-free survival or overall survival in patients with advanced melanoma. These findings indicate that this combination therapy is not effective in this patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jason A. Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed M. Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore Logan, Axel Hauschild, Celeste Lebbe, Harshada Joshi, Wendy Snyder, Janice M. Mehnert
Summary: In a randomized phase II study, the combination of T-VEC and ipilimumab showed greater antitumor activity compared to ipilimumab alone in patients with advanced melanoma. The 5-year outcomes demonstrated long-lasting efficacy and safety for the combination therapy of an oncolytic virus and a checkpoint inhibitor.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Islam Eljilany, Payman Ghasemi Saghand, James Chen, Aakrosh Ratan, Martin McCarter, John Carpten, Howard Colman, Alexandra P. Ikeguchi, Igor Puzanov, Susanne Arnold, Michelle Churchman, Patrick Hwu, Jose Conejo-Garcia, William S. Dalton, George J. Weiner, Issam M. El Naqa, Ahmad A. Tarhini
Summary: In this study, the prognostic value of immunoscore calculated from real-world transcriptomic data was evaluated in patients with advanced malignancies treated with immune checkpoint inhibitors. The results demonstrated that the immunoscore could predict patients at risk of death, with better overall survival observed in patients with intermediate-high immunoscore.
Article
Oncology
Lei Deng, Changchuan Jiang, Kristopher Attwood, Joseph J. Zhao, Stuthi Perimbeti, Chen Hu, Igor Puzanov, Grace K. Dy
Summary: Durable progression-free survivors (dPFSors) over 2 years have been reported among patients with melanoma or non-small-cell lung cancer (NSCLC) who received PD-(L)1 therapy. However, risk of progression still exists and the optimal imaging surveillance interval is unknown.
JCO ONCOLOGY PRACTICE
(2023)
Meeting Abstract
Oncology
Latha Shivakumar, Christine B. Weldon, Ali McBride, Igor Puzanov, Joanne Riemer, Matthew R. Zibelman, Leigh Boehmer
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Meeting Abstract
Medicine, Research & Experimental
Adi Diab, Igor Puzanov, Michele Maio, Brendan Curti, Mehmet Bilen, Karl Lewis, Scott Tykodi, Gregory Daniels, Alexander Spira, Chantale Bernatchez, Salah Eddine Bentebibel, Michael Wong, James Larkin, Ewa Kalinka-Warzocha, Sunny Xie, Sue Currie, Ute Hoch, Wei Lin, Mary Tagliaferri, Stina Singel, Michael Hurwitz
JOURNAL OF TRANSLATIONAL MEDICINE
(2020)
Meeting Abstract
Medicine, Research & Experimental
Adi Diab, Scott Tykodi, Brendan Curti, Daniel Cho, Mike Wong, Igor Puzanov, Karl Lewis, Michele Maio, Gregory A. Daniels, Alexander Spira, Mary Tagliaferri, Alison Hannah, Wendy Clemens, Michael Imperiale, Chantale Bernatchez, Cara Haymaker, Salah Eddine Bentebibel, Jonathan Zalevsky, Ute Hoch, Christie Fanton, Ahsan Rizwan, Sandra Aung, Fiore Cattaruzza, Ernesto Iaccucci, Dariusz Sawka, Mehmet Bilen, Paul Lorigan, Giovanni Grignani, James Larkin, Sekwon Jang, Ewa Kalinka Warzocha, Mario Sznol, Mike Hurwitz
JOURNAL OF TRANSLATIONAL MEDICINE
(2019)
